Previous studies indicated that SGLT2 inhibitors could lower glycemic level either as monotherapy or add-therapy on insulin and other antihyperglycemic drug in DM.[5–8] We are interested in whether SGLT2 inhibitor will be safe and efficient enough as add-on therapy on insulin due to its noninsulin dependent mechanism. The gene discussed is SLC5A2; the disease is diabetes mellitus.